Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"spinraza"”.

  1. Novel protective modifiers in mouse models of spinal muscular atrophy

    … approved, highly efficacious therapy called Spinraza adopts this strategy and has brought promise to the SMA patient community. Despite this breakthrough, it is widely hypothesized that a long-term strategy will require a combinatorial approach to address the complexity of this disease, and …

    missouri Repository record for Novel protective modifiers in mouse models of spinal muscular atrophy (opens in a new tab)

  2. Quality of Life of Children With Spinal Muscular Atrophy: Parents’ Perspectives in Light of New Treatments

    … (SMA) who received supportive care, nusinersen (Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were recruited to complete anonymous online surveys. All surveys included qualitative questions …

    south-carolina Repository record for Quality of Life of Children With Spinal Muscular Atrophy: Parents’ Perspectives in Light of New Treatments (opens in a new tab)

  3. Conceptualisations of Movement (and Movement Loss) in New Zealand Adults Living with Spinal Muscular Atrophy: A Critical Analysis

    … approved funding for children under 18 to access Spinraza (Nusinersen) and Risdiplam (Evrysidi) respectively. However, New Zealand adults with SMA currently remain without access. While the lack of equity in treatment access is concerning, these pharmaceuticals are not curative. Empirical evidence …

    auckland-tech Repository record for Conceptualisations of Movement (and Movement Loss) in New Zealand Adults Living with Spinal Muscular Atrophy: A Critical Analysis (opens in a new tab)

  4. Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy

    Importance: Patients with severe forms of Spinal Muscular Atrophy (SMA) depend on costly supportive care interventions. Few studies have evaluated how the clinical effectiveness of nusinersen, the first FDA approved treatment for SMA, affects healthcare costs. Objective: To assess the effect of …

    washington Repository record for Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy (opens in a new tab)